Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Carbamazepine Clear all
Completed Not applicable Interventional Results available

Oxcarbazepine Versus Placebo in Childhood Autism

NCT00467753
View directory record Official record
Conditions
Autism
Interventions
Oxcarbazepine, Placebo/sugar pill
Drug · Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
5 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Sep 1, 2026, 10:44 PM EDT
Terminated Phase 2 Interventional Results available

Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency

NCT01379469
View directory record Official record
Conditions
Alpha-1-antitrypsin Deficiency, Liver Cirrhosis
Interventions
Drug-Carbamazepine (Tegretol XR), Carbamazepine (Tegretol XR) Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
14 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 1, 2026, 10:44 PM EDT
Completed Phase 2 Interventional

Carbamazepine Treatment for Cocaine Dependence - 5

NCT00000191
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Carbamazepine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 51 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 1994
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 1, 2026, 10:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions

NCT06671405
View directory record Official record
Conditions
Dyslipidaemia
Interventions
AZD0780, Itraconazole, Carbamazepine, Midazolam, Ethinyl estradiol/levonorgestrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 1, 2026, 10:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants

NCT06751017
View directory record Official record
Conditions
COVID-19
Interventions
S-892216, Carbamazepine
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 1, 2026, 10:44 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram

NCT00562861
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression
Interventions
citalopram + mood stabilizer, placebo + mood stabilizer
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 1, 2026, 10:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)

NCT06596668
View directory record Official record
Conditions
Healthy
Interventions
bomedemstat, carbamazepine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 1, 2026, 10:44 PM EDT
Completed Phase 4 Interventional Results available

Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations

NCT02214615
View directory record Official record
Conditions
Erythromelalgia
Interventions
Carbamazepine, Placebo
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Sep 1, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

NCT00908349
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Oxcarbazepine XR
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 66 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
20
States / cities
Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 1, 2026, 10:44 PM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 1, 2026, 10:44 PM EDT
Completed Phase 3 Interventional

Pediatric Epilepsy Study

NCT00050934
View directory record Official record
Conditions
Epilepsy, Epilepsies, Partial
Interventions
oxcarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 3 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
26
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Sep 1, 2026, 10:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Premenstrual Dysphoric Disorder and Antiepileptic Drugs

NCT00612235
View directory record Official record
Conditions
Epilepsy
Interventions
Lamotrigine, Levetiracetam, Carbamazepine, No Intervention
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Sep 1, 2026, 10:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects

NCT01967771
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG, CBZ
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Sep 1, 2026, 10:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants

NCT05860933
View directory record Official record
Conditions
Healthy
Interventions
LY3537982, Itraconazole, Carbamazepine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Sep 1, 2026, 10:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine

NCT05418582
View directory record Official record
Conditions
Healthy Subjects
Interventions
DZD9008 and intraconazole, DZD9008 and carbamazepine
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 1, 2026, 10:44 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures

NCT00772603
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Placebo, 2400mg SPN-804, 1200mg SPN-804
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
23
States / cities
Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 1, 2026, 10:44 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Developmental Delay in Children Exposed During Pregnancy to Either Lamotrigine,Sodium Valproate, or Carbamazepine

NCT01097720
View directory record Official record
Conditions
Autism, Developmental Delay, Birth Defects
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
36 Months to 83 Months
Enrollment
298 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Sep 1, 2026, 10:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects

NCT04783753
View directory record Official record
Conditions
Hepatitis B
Interventions
EDP-514, Itraconazole, Carbamazepin, Quinidine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Sep 1, 2026, 10:44 PM EDT
Withdrawn Phase 1 Interventional

Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma

NCT00734864
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioma
Interventions
enzyme-inducing anti-epileptic drugs
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Sep 1, 2026, 10:44 PM EDT
Completed Phase 1 Interventional

Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas

NCT00612638
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temodar, O6-BG, and Irinotecan
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 1, 2026, 10:44 PM EDT
Completed No phase listed Observational Results available

Pathogenesis of Adverse Drug Reactions

NCT00224952
View directory record Official record
Conditions
Seizures
Interventions
No intervention; Urine Collection
Other
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Year to 16 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
3
States / cities
Louisville, Kentucky • Kansas City, Missouri • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 1, 2026, 10:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

NCT05594602
View directory record Official record
Conditions
COVID-19
Interventions
EDP-235, Itraconazole, Carbamazepine, Quinidine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Sep 1, 2026, 10:44 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers

NCT06672900
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Carbamazepine, Itraconazole (Sporanox), ALG-000184
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 1, 2026, 10:44 PM EDT
Terminated Phase 4 Interventional

DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder

NCT02623504
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Carbamazepine, Placebo
Drug
Lead sponsor
Validus Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Orlando, Florida • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Sep 1, 2026, 10:44 PM EDT